15 results on '"Umair Ilyas"'
Search Results
2. Corrigendum: Identification and validation of differentially expressed genes for targeted therapy in NSCLC using integrated bioinformatics analysis
- Author
-
Reem Altaf, Umair Ilyas, Anmei Ma, and Meiqi Shi
- Subjects
NSCLC ,mutational analysis ,differentially expressed genes ,microarray ,bioinformatics ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Published
- 2024
- Full Text
- View/download PDF
3. Identification and validation of differentially expressed genes for targeted therapy in NSCLC using integrated bioinformatics analysis
- Author
-
Reem Altaf, Umair Ilyas, Anmei Ma, and Meiqi Shi
- Subjects
NSCLC ,mutational analysis ,differentially expressed genes ,microarray ,bioinformatics ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
BackgroundDespite the high prevalence of lung cancer, with a five-year survival rate of only 23%, the underlying molecular mechanisms of non-small cell lung cancer (NSCLC) remain unknown. There is a great need to identify reliable candidate biomarker genes for early diagnosis and targeted therapeutic strategies to prevent cancer progression.MethodsIn this study, four datasets obtained from the Gene Expression Omnibus were evaluated for NSCLC- associated differentially expressed genes (DEGs) using bioinformatics analysis. About 10 common significant DEGs were shortlisted based on their p-value and FDR (DOCK4, ID2, SASH1, NPR1, GJA4, TBX2, CD24, HBEGF, GATA3, and DDR1). The expression of significant genes was validated using experimental data obtained from TCGA and the Human Protein Atlas database. The human proteomic data for post- translational modifications was used to interpret the mutations in these genes.ResultsValidation of DEGs revealed a significant difference in the expression of hub genes in normal and tumor tissues. Mutation analysis revealed 22.69%, 48.95%, and 47.21% sequence predicted disordered regions of DOCK4, GJA4, and HBEGF, respectively. The gene-gene and drug-gene network analysis revealed important interactions between genes and chemicals suggesting they could act as probable drug targets. The system-level network showed important interactions between these genes, and the drug interaction network showed that these genes are affected by several types of chemicals that could serve as potential drug targets.ConclusionsThe study demonstrates the importance of systemic genetics in identifying potential drug- targeted therapies for NSCLC. The integrative system- level approach should contribute to a better understanding of disease etiology and may accelerate drug discovery for many cancer types.
- Published
- 2023
- Full Text
- View/download PDF
4. Synthesis, Biological Evaluation, 2D-QSAR, and Molecular Simulation Studies of Dihydropyrimidinone Derivatives as Alkaline Phosphatase Inhibitors
- Author
-
Reem Altaf, Humaira Nadeem, Muhammad Nasir Iqbal, Umair Ilyas, Zaman Ashraf, Muhammad Imran, and Syed Aun Muhammad
- Subjects
Chemistry ,QD1-999 - Published
- 2022
- Full Text
- View/download PDF
5. Virtual screening and drug repositioning of FDA-approved drugs from the ZINC database to identify the potential hTERT inhibitors
- Author
-
Hasan Afzaal, Reem Altaf, Umair Ilyas, Shaiq Uz Zaman, Syed Damin Abbas Hamdani, Saifullah Khan, Hajra Zafar, Mustafeez Mujtaba Babar, and Yongtao Duan
- Subjects
hTERT inhibitors ,virtual screening ,drug repurposing ,molecular dynamic simulation ,anticancer ,Therapeutics. Pharmacology ,RM1-950 - Abstract
The length of the telomeres is maintained with the help of the enzyme telomerase constituting of two components, namely, a core reverse transcriptase protein (hTERT) and RNA (hTR). It serves as a significant and universal cancer target. In silico approaches play a crucial role in accelerating drug development processes, especially cancer drug repurposing is an attractive approach. The current study is aimed at the repurposing of FDA-approved drugs for their potential role as hTERT inhibitors. Accordingly, a library of 2,915 sets of FDA-approved drugs was generated from the ZINC database in order to screen for novel hTERT inhibitors; later on, these were subjected to molecular docking analysis. The top two hits, ZINC03784182 and ZINC01530694, were shortlisted for molecular dynamic simulation studies at 100 ns based on their binding scores. The RMSD, RMSF, Rg, SASA, and interaction energies were calculated for a 100-ns simulation period. The hit compounds were also analyzed for antitumor activity, and the results revealed promising cytotoxic activities of these compounds. The study has revealed the potential application of these drugs as antitumor agents that can be useful in treating cancer and can serve as lead compounds for further in vivo, in vitro, and clinical studies.
- Published
- 2022
- Full Text
- View/download PDF
6. Investigation of anti-diabetic potential and molecular simulation studies of dihydropyrimidinone derivatives
- Author
-
Umair Ilyas, Bisma Nazir, Reem Altaf, Syed Aun Muhammad, Hajra Zafar, Ana Cláudia Paiva-Santos, Muhammad Abbas, and Yongtao Duan
- Subjects
Dihydropyrimidinones ,alpha-glucosidase ,molecular docking ,anti-diabetic ,in-silico ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
In an attempt to find new targets for α-amylase and α-glucosidase for the treatment of type 2 diabetes mellitus, the present study aims in determining the anti-diabetic potential of synthesized dihydropyrimidinone derivatives. The in vitro α-glucosidase and α-amylase inhibitory activity was performed and the molecular docking analysis of the ligand in the active binding site of target protein was determined. The results revealed significant percent inhibition of α-glucosidase by the compound 6-benzyl-4-(4-hydroxyphenyl)-3,4,6,7-tetrahydro-1H-pyrrolo[3,4-d]pyrimidine-2,5-dione (compound A). The active compound showed 81.99% inhibition when compared to standard ascorbic acid having percent inhibition 81.18%. The IC50 of active compound (A) showed to be 1.02 µg/ml. The molecular docking analysis revealed that the ligand bound to the active binding site of protein with the lowest binding energy of -7.9 kcal/mol that was also significantly similar to standard having -7.8 kcal/mol binding energy. The molecular dynamic simulation studies also revealed stable binding of ligand in the active binding site of protein with low RMSD of 1.7 Å similar to the protein RMSD 1.6Å In conclusion, the study revealed a potential new target against α-glucosidase to treat type 2 diabetes mellitus.
- Published
- 2022
- Full Text
- View/download PDF
7. Herbal therapies in gastrointestinal and hepatic disorders: An evidence-based clinical review
- Author
-
Yongfang Yao, Murad Habib, Hajra Fazeelat Bajwa, Anina Qureshi, Rameesha Fareed, Reem Altaf, Umair Ilyas, Yongtao Duan, and Muhammad Abbas
- Subjects
ethnopharmacology ,herbal medication ,GIT ,liver ,treatment ,Therapeutics. Pharmacology ,RM1-950 - Abstract
The gastrointestinal tract (GIT) and the liver constitute the major organs of the human body. Indeed, the very survival of the human body depends on their proper functioning. Because the GIT is a huge and complex organ system, the maintenance of proper GIT and liver health is an arduous task. GIT disturbances such as diarrhea, stomach ache, flatulence, constipation, nausea, and vomiting are very common, and they contribute to a significant burden on the healthcare system. Pharmacies are full of over-the-counter pharmacological drugs to alleviate its common conditions. However, these drugs do not always prove to be fully effective and patients have to keep on living with these ailments without a proper and long-term solution. The aim of this review article is to present a practical reference guide to the role of herbal medicines in dealing with gastrointestinal and hepatic disorders, which is supported by systematic reviews and evidence-based trials. People have depended on herbal medications for centuries for the treatment of various ailments of the GIT, liver, and other organ system problems. Recently, this trend of incorporating herbal medication for the treatment of various diseases in both developing and developed countries have surged. Many people continue to use herbal medications, even though substantial data about their efficacy, uses, and toxicological effects do not exist. In addition, while herbal medicines have enormous benefits in both the prevention and the treatment of medical ailments, they can also have toxicological effects. It is, therefore, of the utmost importance that appropriate time, energy, and resources are spent on the development of ethnopharmacology. In addition, herbal products should be classified in a pattern similar to pharmacological medications, including their uses, side effects, mechanism of action, efficacy, and so on.
- Published
- 2022
- Full Text
- View/download PDF
8. Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment
- Author
-
Reem Altaf, Sarmad Sheraz Jadoon, Syed Aun Muhammad, Umair Ilyas, and Yongtao Duan
- Subjects
lung cancer ,immune checkpoint inhibitors ,immunotherapy ,non-small lung cancer ,chemotherapy ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Lung cancer is one of the deadliest types of cancer responsible for thousands of cancer-related deaths. Its treatment has remained a challenge for researchers, but an increase in the knowledge of molecular pathways and biology of lung cancer has dramatically changed its management in recent decades. Immunotherapies and immunomodulation of lung cancer have previously failed for a long time but thanks to continuous research work and enthusiasm, now, this field is emerging as a novel effective therapy. Now, it is hope with potential benefits and promising results in the treatment of lung cancer. This review article focuses on immune checkpoints inhibitors: CTLA-4 inhibitors (ipilimumab and tremelimumab) and PDL-1 inhibitors (durvalumab and atezolizumab) that can be blocked to treat lung carcinoma. It is also focused on critically analyzing different studies and clinical trials to determine the potential benefits, risks, and adverse events associated with immunotherapeutic treatment.
- Published
- 2022
- Full Text
- View/download PDF
9. A meta-analysis of genome-wide gene expression differences identifies promising targets for type 2 diabetes mellitus
- Author
-
Tao Huang, Bisma Nazir, Reem Altaf, Bolun Zang, Hajra Zafar, Ana Cláudia Paiva-Santos, Nabeela Niaz, Muhammad Imran, Yongtao Duan, Muhammad Abbas, and Umair Ilyas
- Subjects
type 2 diabetes mellitus ,gene ontology ,differential expression analysis ,R programming ,system biology ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Aims/introductionDue to the heterogeneous nature of type 2 diabetes mellitus and its complex effects on hemodynamics, there is a need to identify new candidate markers which are involved in the development of type 2 diabetes mellitus (DM) and can serve as potential targets. As the global diabetes prevalence in 2019 was estimated as 9.3% (463 million people), rising to 10.2% (578 million) by 2030 and 10.9% (700 million) by 2045, the need to limit this rapid prevalence is of concern. The study aims to identify the possible biomarkers of type 2 diabetes mellitus with the help of the system biology approach using R programming.Materials and methodsSeveral target proteins that were found to be associated with the source genes were further curated for their role in type 2 diabetes mellitus. The differential expression analysis provided 50 differentially expressed genes by pairwise comparison between the biologically comparable groups out of which eight differentially expressed genes were short-listed. These DEGs were as follows: MCL1, PTX3, CYP3A4, PTGS1, SSTR2, SERPINA3, TDO2, and GALNT7.ResultsThe cluster analysis showed clear differences between the control and treated groups. The functional relationship of the signature genes showed a protein–protein interaction network with the target protein. Moreover, several transcriptional factors such as DBX2, HOXB7, POU3F4, MSX2, EBF1, and E4F1 showed association with these identified differentially expressed genes.ConclusionsThe study highlighted the important markers for diabetes mellitus that have shown interaction with other proteins having a role in the progression of diabetes mellitus that can serve as new targets in the management of DM.
- Published
- 2022
- Full Text
- View/download PDF
10. Nanostructured Lipid Carrier-Based Delivery of Pioglitazone for Treatment of Type 2 Diabetes
- Author
-
Umair Ilyas, Muhammad Asif, Minglian Wang, Reem Altaf, Hajra Zafar, Mirza Muhammad Faran Ashraf Baig, Ana Cláudia Paiva-Santos, and Muhammad Abbas
- Subjects
pioglitazone ,poor aqueous solubility ,NLCs ,nanoparticles ,diabetes ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Pioglitazone (PGZ) is utilized as a therapeutic agent in the management of (type 2) diabetes to control blood glucose levels. The existing research work was intended to make and optimize PGZ-containing NLCs (nanostructured lipid carriers). The fabricated nanostructured lipid carrier preparation was optimized by using different concentrations of the surfactants (Tween 80 and Span 80) and solid lipid (Compritol® 888 ATO) and liquid lipid (Labrasol®) while keeping the concentration of drug (PGZ), and co-surfactants (poloxamer 188) the same. The optimized NLC formulation (PGZ-NLCs) was further assessed for physical and chemical characterization, in vitro PGZ release, and stability studies. The optimized PGZ-NLCs have shown an average diameter of 150.4 nm, EE of 92.53%, PDI value of 0.076, and zeta-potential of −29.1 mV, correspondingly. The DSC thermal analysis and XRD diffractograms had not presented the spectrum of PGZ, confirming the comprehensive encapsulation of PGZ in the lipid core. PGZ-NLCs showed significantly extended release (51% in 24 h) compared to the unformulated PGZ. Our study findings confirmed that PGZ-NLCs can be a promising drug delivery system for the treatment of type 2 diabetes.
- Published
- 2022
- Full Text
- View/download PDF
11. Genome-scale meta-analysis of breast cancer datasets identifies promising targets for drug development
- Author
-
Reem Altaf, Humaira Nadeem, Mustafeez Mujtaba Babar, Umair Ilyas, and Syed Aun Muhammad
- Subjects
Breast cancer ,Microarray datasets ,Pathway enrichment analysis ,Gene ontology ,miRNA ,Drug-gene network ,Biology (General) ,QH301-705.5 - Abstract
Abstract Background Because of the highly heterogeneous nature of breast cancer, each subtype differs in response to several treatment regimens. This has limited the therapeutic options for metastatic breast cancer disease requiring exploration of diverse therapeutic models to target tumor specific biomarkers. Methods Differentially expressed breast cancer genes identified through extensive data mapping were studied for their interaction with other target proteins involved in breast cancer progression. The molecular mechanisms by which these signature genes are involved in breast cancer metastasis were also studied through pathway analysis. The potential drug targets for these genes were also identified. Results From 50 DEGs, 20 genes were identified based on fold change and p-value and the data curation of these genes helped in shortlisting 8 potential gene signatures that can be used as potential candidates for breast cancer. Their network and pathway analysis clarified the role of these genes in breast cancer and their interaction with other signaling pathways involved in the progression of disease metastasis. The miRNA targets identified through miRDB predictor provided potential miRNA targets for these genes that can be involved in breast cancer progression. Several FDA approved drug targets were identified for the signature genes easing the therapeutic options for breast cancer treatment. Conclusion The study provides a more clarified role of signature genes, their interaction with other genes as well as signaling pathways. The miRNA prediction and the potential drugs identified will aid in assessing the role of these targets in breast cancer.
- Published
- 2021
- Full Text
- View/download PDF
12. Genome wide meta-analysis of cDNA datasets reveals new target gene signatures of colorectal cancer based on systems biology approach
- Author
-
Umair Ilyas, Shaiq uz Zaman, Reem Altaf, Humaira Nadeem, and Syed Aun Muhammad
- Subjects
Colorectal cancer ,Microarrays ,Functional genomics ,PPI network ,Biomarkers ,Biology (General) ,QH301-705.5 - Abstract
Abstract Background Colorectal cancer is known to be the most common type of cancer worldwide with high disease-related mortality. It is the third most common cancer in men and women and is the second major cause of death globally due to cancer. It is a complicated and fatal disease comprising of a group of molecular heterogeneous disorders. Results This study identifies the potential biomarkers of CRC through differentially expressed analysis, system biology, and proteomic analysis. Ten publicly available microarray datasets were analyzed and seven potential biomarkers were identified from the list of differentially expressed genes having a p value
- Published
- 2020
- Full Text
- View/download PDF
13. 1,3,4-Oxadiazole Derivative Attenuates Chronic Constriction Injury Induced Neuropathic Pain: A Computational, Behavioral, and Molecular Approach
- Author
-
Muhammad Faheem, Syed Hussain Ali, Abdul Waheed Khan, Mahboob Alam, Umair Ilyas, Muhammad Zahoor, Muhammad Umar Khayam Sahibzada, Sidra Khalid, Riaz Ullah, Ali S. Alqahtani, and Abdulaziz M. Alqahtani
- Subjects
In-silico ,chronic constriction injury ,hyperalgesia ,neuro-protective ,IL-6 ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
The production and up-regulation of inflammatory mediators are contributing factors for the development and maintenance of neuropathic pain. In the present study, the post-treatment of synthetic 1,3,4 oxadiazole derivative (B3) for its neuroprotective potential in chronic constriction injury-induced neuropathic pain was applied. In-silico studies were carried out through Auto Dock, PyRx, and DSV to obtain the possible binding and interactions of the ligands (B3) with COX-2, IL-6, and iNOS. The sciatic nerve of the anesthetized rat was constricted with sutures 3/0. Treatment with 1,3,4-oxadiazole derivative was started a day after surgery and continued until the 14th day. All behavioral studies were executed on day 0, 3rd, 7th, 10th, and 14th. The sciatic nerve and spinal cord were collected for further molecular analysis. The interactions in the form of hydrogen bonding stabilizes the ligand target complex. B3 showed three hydrogen bonds with IL-6. B3, in addition to correcting paw posture/deformation induced by CCI, attenuates hyperalgesia (p < 0.001) and allodynia (p < 0.001). B3 significantly raised the level of GST and GSH in both the sciatic nerve and spinal cord and reduced the LPO and iNOS (p < 0.001). B3 attenuates the pathological changes induced by nerve injury, which was confirmed by H&E staining and IHC examination. B3 down-regulates the over-expression of the inflammatory mediator IL-6 and hence provides neuroprotective effects in CCI-induced pain. The results demonstrate that B3 possess anti-nociceptive and anti-hyperalgesic effects and thus minimizes pain perception and inflammation. The possible underlying mechanism for the neuroprotective effect of B3 probably may be mediated through IL-6.
- Published
- 2020
- Full Text
- View/download PDF
14. Correction to: Genome wide meta-analysis of cDNA datasets reveals new target gene signatures of colorectal cancer based on systems biology approach
- Author
-
Umair Ilyas, Shahiq uz Zaman, Reem Altaf, Humaira Nadeem, and Syed Aun Muhammad
- Subjects
Biology (General) ,QH301-705.5 - Abstract
An amendment to this paper has been published and can be accessed via the original article.
- Published
- 2020
- Full Text
- View/download PDF
15. Insilico study of anti-carcinogenic lysyl oxidase-like 2 inhibitors.
- Author
-
Syed Aun Muhammad, Amjad Ali 0001, Tariq Ismail, Rehan Zafar Paracha, Umair Ilyas, and Jamil Ahmad
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.